Nalaganje...

Evaluation of the Dual-Chamber Pen Design for the Injection of Exenatide Once Weekly for the Treatment of Type 2 Diabetes

BACKGROUND: Exenatide once weekly, an injectable glucagon-like peptide-1 receptor agonist, has been shown to reduce A1C, fasting glucose, and body weight in patients with type 2 diabetes. Exenatide 2.0 mg is dispersed in poly-(D,L-lactide-co-glycolide) polymer microspheres, which require resuspensio...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Diabetes Sci Technol
Main Authors: LaRue, Susan, Malloy, Jaret
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publications 2015
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4525643/
https://ncbi.nlm.nih.gov/pubmed/25759181
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1932296815576186
Oznake: Označite
Brez oznak, prvi označite!